Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $2.13, $0.43 better than the analyst estimate of $1.70. Revenue for the quarter came in at $617.5 million versus the consensus estimate of $609.02 million.

2019 Financial Outlook

For the full year 2019, the company anticipates currency-neutral revenue growth of approximately 4.0 to 4.5 percent and improved profitability with an estimated non-GAAP operating margin of 12.5 to 13.0 percent. Management will discuss this outlook in greater detail on the fourth-quarter and full-year 2018 financial results conference call.

“Looking ahead to 2019, we expect another year of growth in many of our key product areas and geographies,” Mr. Schwartz said. “The 2019 anticipated expansion in our non-GAAP operating margin by nearly 200 basis points represents another significant step toward achieving our longer term goal of an adjusted EBITDA margin of 20 percent in 2020.”

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.